biostudies-literatureFeris EJNCI NIH HHS2147-2157https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522838biostudies-literatureUnknown12(21)Mechanism-based targeted therapies have exhibited remarkable success in treating otherwise untreatable or unresectable cancers. Novel targeted therapies that correct dysregulated transcriptional programs in cancer are an unmet medical need. The transcription factor MYC is the most frequently amplified gene in human cancer and is overexpressed because of mutations in an array of oncogenic signaling pathways. The fact that many cancer cells cannot survive without MYC - a phenomenon termed "MYC addiction" - provides a compelling case for the development of MYC-specific targeted therapies. We propose a new strategy to inhibit MYC function by disrupting its essential interaction with TRRAP using small molecules. To achieve our goal, we developed a platform using luminescence complementation forOncotargetLuminescence complementation technology for the identification of MYC:TRRAP inhibitors.PMC8522838P30 CA023108R01 CA055248Feris EJCole MDHinds JWfalseLuminescence complementation technology for the identification of MYC:TRRAP inhibitors.Mechanism-based targeted therapies have exhibited remarkable success in treating otherwise untreatable or unresectable cancers. Novel targeted therapies that correct dysregulated transcriptional programs in cancer are an unmet medical need. The transcription factor MYC is the most frequently amplified gene in human cancer and is overexpressed because of mutations in an array of oncogenic signaling pathways. The fact that many cancer cells cannot survive without MYC - a phenomenon termed "MYC addiction" - provides a compelling case for the development of MYC-specific targeted therapies. We propose a new strategy to inhibit MYC function by disrupting its essential interaction with TRRAP using small molecules. To achieve our goal, we developed a platform using luminescence complementation for2021-01-01T00:00:00Z2021 Oct2026-05-10T00:48:31.166Z2025-04-04T12:03:19.757ZS-EPMC85228383467604710.18632/oncotarget.28078